(Total Views: 112)
Posted On: 04/06/2022 11:40:51 AM
Post# of 25100
$AZN News Article - ULTOMIRIS (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks https://marketwirenews.com/news-releases/ulto...99850.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
